期刊
JOURNAL OF GENERAL INTERNAL MEDICINE
卷 37, 期 16, 页码 4037-4046出版社
SPRINGER
DOI: 10.1007/s11606-022-07807-8
关键词
analgesics; opioid; opioid-related disorders; drug evaluation; VA
资金
- 2019 PAINWeek Annual Meeting
- 2019 VA/DoD Suicide Prevention Conference
- 2019 VA Innovation Experience
- 2018 Rx Drug Abuse Heroin
- Healthcare Foundation of New Jersey, by National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network Data and Safety Monitoring
- Health Services Research and Development [16-078]
- Patient-Centered Outcomes Research Institute (EMPOWER study (Effective Management of Pain and Opioid-Free Ways to Enhance Relief))
This study describes the changes in opioid de-prescribing practices after the implementation of the Opioid Safety Initiative (OSI). The results suggest that veterans who discontinued high-dose long-term opioids in FY17 were more optimally managed compared to those in FY13. However, the interpretation of the findings is limited due to the study design.
Background The Opioid Safety Initiative (OSI) was implemented in 2013 to enhance the safe and appropriate use of opioids in the Veterans Health Administration (VA). Opioid use decreased nationally in subsequent years, but characterization of opioid de-prescribing practices has not been well established. Objectives To describe changes in patient characteristics and patterns of de-prescribing since OSI implementation for opioid users at > 90 morphine equivalent daily dose for at least 90 days for those that discontinued opioids within the VA. Design Retrospective observational pre-post intervention medication use evaluation using VA data and electronic health records to identify differences in opioid de-prescribing between fiscal year 2013 (FY13; early OSI) and FY17 (late OSI). Reviewers' insights for local opioid management and de-prescribing practices collected through web-based post-data collection survey. Participants Veterans prescribed high-dose long-term opioid therapy in FY13 and FY17 who subsequently discontinued opioids at 27 VA medical centers. Main measures Chart review data from local facility reviewers identified socioeconomic characteristics, opioid de-prescribing rationale (e.g., risk-benefit, diversion) and practices (e.g., rate of opioid discontinuation, taper monitoring activities, withdrawal monitoring), and outcomes following discontinuation. Key Results Among 315 patients in FY13 and 322 patients in FY17 with opioid discontinuation, discontinuation rationale focused on diversion in FY13 and risk-benefit in FY17. Clinical pharmacists and pain management specialists had increased involvement in FY17 opioid discontinuations (36% versus 16%). Of all discontinuations, 56% of patients were tapered in FY13 versus 70% of patients in FY17. Tapering plans were longer in FY17 than in FY13 (163 days versus 65 days). Transitions to non-opioid pain therapy following opioid discontinuation were higher in FY17 compared to FY13 (70% versus 60%). Conclusions Veterans discontinued from high-dose long-term opioids in FY17 were more optimally managed compared to those in FY13. Findings suggest improvements in opioid de-prescribing following OSI implementation, but interpretation is limited by study design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据